Everolimus News and Research

RSS

AB Sciex launches immunosuppressants kit to improve health care

Every organ transplant patient in the world faces the potential danger of his/her body rejecting a new organ, such as a heart, kidney or liver. Immunosuppressant drugs are required to help prevent rejection.

2 Apr 2014

Boston Scientific presents new data on cardiology-related clinical trials at ACC 2014

Reinforcing its position as a global leader in bringing new therapies to patients with heart and cardiovascular disease, Boston Scientific Corporation (NYSE: BSX) reported favorable results in studies related to cardiac resynchronization therapy (CRT), platinum chromium stent platforms and transcatheter aortic valve replacement (TAVR).

2 Apr 2014

Rexahn provides updates on clinical development programs, reports full-year 2013 financial results

Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and Year for the year ended December 31, 2013.

24 Mar 2014

Patient with advanced bladder cancer shows complete response to everolimus and pazopanib drugs

A patient with advanced bladder cancer experienced a complete response for 14 months to the drug combination everolimus and pazopanib in a phase I trial, and genomic profiling of his tumor revealed two alterations that may have caused this exceptional response, according to a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

13 Mar 2014

Everolimus fails to boost advanced NSCLC response

Phase II trial findings have ruled out a combination of erlotinib and everolimus for advanced non-small-cell lung cancer patients with progression after chemotherapy.

28 Jan 2014

The Medicines Company, Boston Scientific announce co-promotion agreement for Promus PREMIER stent system

Boston Scientific Corporation and The Medicines Company announce a co-promotion agreement for the Boston Scientific Promus PREMIER™ Everolimus-Eluting Platinum Chromium Coronary Stent System.

6 Dec 2013

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Novartis will present updates on its broad cancer portfolio with more than 240 abstracts at the upcoming American Society of Hematology (ASH) annual meeting and CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

4 Dec 2013

Nanopharmaceutical drug shows promise for cancers that resist antiangiogenic drugs

The nanopharmaceutical drug CRLX101 is showing promise as a potential new treatment for cancers that develop resistance to antiangiogenic drugs and radiation therapy, according to clinical trial results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19 - 23.

22 Oct 2013

First Phase II study: Everolimus drug slows spread of advanced papillary kidney cancer

The first Phase II study to investigate the use of the anti-cancer drug, everolimus, for the initial treatment of advanced papillary kidney cancer has shown that it is successful in slowing or preventing the spread of the disease, according to research to be presented today (Sunday) at the 2013 European Cancer Congress.

29 Sep 2013

CRF to present groundbreaking clinical trial findings at TCT 2013 scientific symposium

The Cardiovascular Research Foundation (CRF) has announced the late breaking trials and first report investigations that will be presented at next month's Transcatheter Cardiovascular Therapeutics (TCT) 2013 scientific symposium.

21 Sep 2013

Study demonstrates effectiveness of everolimus for TSC patients

A drug originally developed to prevent the rejection of transplanted organs has now been shown to dramatically reduce seizures in patients with tuberous sclerosis complex - a genetic disease characterized by benign tumors on multiple organ systems.

16 Jul 2013

Abbott starts ABSORB Japan trial to evaluate Absorb BVS in patients with CAD

Abbott today announced that it has initiated the ABSORB Japan randomized controlled clinical trial to evaluate the Absorb Bioresorbable Vascular Scaffold in patients with coronary artery disease, the most common form of heart disease.

11 Jun 2013

Exelixis starts phase 3 pivotal trial of cabozantinib for treatment of metastatic renal cell carcinoma

Exelixis, Inc. today announced it has initiated METEOR, a phase 3 pivotal trial comparing cabozantinib to everolimus in patients with metastatic renal cell carcinoma who have experienced disease progression following treatment with at least one prior VEGFR tyrosine kinase inhibitor.

31 May 2013

Everolimus reverses trastuzumab resistance in early HER-2 positive breast cancer

A study that aimed to understand how the cancer drug everolimus helps overcome the resistance breast cancers can develop to trastuzumab has left researchers contemplating a puzzle.

3 May 2013

Study brings opportunities of personalised therapy for breast cancer a step closer

A study led by prominent breast cancer experts from Europe and the US has revealed a number of potentially important prospects for targeted therapies, and brings opportunities of truly personalised therapy for breast cancer a step closer, researchers said at the 5th IMPAKT Breast Cancer Conference in Brussels, Belgium.

2 May 2013

Everolimus News and Research

AB Sciex launches immunosuppressants kit to improve health care

Boston Scientific presents new data on cardiology-related clinical trials at ACC 2014

Rexahn provides updates on clinical development programs, reports full-year 2013 financial results

Patient with advanced bladder cancer shows complete response to everolimus and pazopanib drugs

Everolimus fails to boost advanced NSCLC response

The Medicines Company, Boston Scientific announce co-promotion agreement for Promus PREMIER stent system

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Nanopharmaceutical drug shows promise for cancers that resist antiangiogenic drugs

First Phase II study: Everolimus drug slows spread of advanced papillary kidney cancer

CRF to present groundbreaking clinical trial findings at TCT 2013 scientific symposium

Study demonstrates effectiveness of everolimus for TSC patients

Abbott starts ABSORB Japan trial to evaluate Absorb BVS in patients with CAD

Exelixis starts phase 3 pivotal trial of cabozantinib for treatment of metastatic renal cell carcinoma

Everolimus reverses trastuzumab resistance in early HER-2 positive breast cancer

Study brings opportunities of personalised therapy for breast cancer a step closer

FDA approves Novartis’ Zortress to prevent organ rejection after liver transplantation in adults

HRI to begin enrollment in RAD001 Phase II trial for Neurofibromatosis Type-2

New medication could help patients with renal tumours triggered by tuberous sclerosis

Oral toxicity is frequent limitation of mTOR therapy

Everolimus treatment option for tuberous sclerosis patients

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News